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Response rate and toxicity of second-line therapy with docetaxel (75mgm
 2) or docetaxel, irinotecan, and lenogastrim (60mgm
 2,
200mgm
 2, and 150mgm
 2day
 1, respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer.
Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.
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Treatment with platinum-based chemotherapy improves survival
and quality of life in patients with advanced non-small-cell
lung cancer (NSCLC) (Souquet et al, 1993; Non-small Cell
Lung Cancer Collaborative Group, 1995; Cullen et al, 1999;
Anderson et al, 2000; Ranson et al, 2000; Schiller et al, 2002).
Since two trials demonstrated clinically beneficial effects of
docetaxel in second-line setting (Fossella et al, 2000; Shepherd
et al, 2000), docetaxel 75mgm
 2 is currently considered the
standard regimen to which other experimental schedules should be
compared.
Irinotecan, a semisynthetic water-soluble analogue of
camptothecin, has shown activity in NSCLC patients as single
agent and in combination with docetaxel (Fukuoka et al, 1992;
Adjei et al, 2000; Masuda et al, 2000; Satouchi et al, 2001;
Negoro et al, 2003). Moreover, Irinotecan demonstrated activity
as single agent in pretreated patients (Sanchez et al, 2003). In our
trial the efficacy of the combination of docetaxel and irino-
tecan compared to single-agent docetaxel as second-line
treatment in NSCLC was investigated. Primary end point of this
randomised phase II study was tumour response rate. Secondary
end points were toxicity, progression-free survival and
overall survival. The treatment regimen was based on a phase II
study, which demonstrated activity of docetaxel and irinotecan
in patients with recurrent ovarian cancer (Ma ¨enpa ¨a ¨ et al, 1999).
In this study, neutropenia was the main toxicity; therefore, we
added a granulocyte colony-stimulating factor to our treatment
regimen.
PATIENTS AND METHODS
Patient selection
Inclusion criteria for enrolment in the trial were age X18 years,
stage IIIb–IV NSCLC, failure or relapse after first-line chemother-
apy, at least one measurable or evaluable tumour lesion,
performance status p2 according to the Eastern Cooperative
Oncology Group scale, life expectancy of X3 months, adequate
bone marrow reserve (neutrophils X1.5 10
9l
 1,p l a t e l e t s
X100 10
9l
 1,h a e m o g l o b i nX6.2mmoll
 1), renal function (ser-
um creatinine p1.25 times the upper normal limit), and liver
function (serum bilirubinpthe upper limit of the institutional
reference value, serum alanine aminotransferase (ALAT) and serum
aspartate aminotransferase (ASAT) p2.5 times the upper normal
limit, alkaline phosphatase p5 times the upper normal limit). Prior
radiotherapy was allowed as long as the irradiated area did not
contain the sole measurable or evaluable lesion. Exclusion criteria
were active infection, second primary malignancies (except
carcinoma in situ of the cervix, adequately treated basal cell
carcinoma of the skin, and other cancer curatively treated without
recurrence for at least 5 years), symptomatic brain metastases,
inflammatory bowel diseases, symptomatic peripheral neuropathy
Xgrade 2 according to the Common Toxicity Criteria (CTC) of the
National Cancer Institute (version 2.0), serious cardiac diseases,
contraindications for use of corticosteroids, pregnancy, breast-
feeding, or reproductive potential without implementing adequate
contraceptive measures. Local medical ethics committees of all
hospitals approved the protocol. All patients gave informed consent.
Treatment
Patients were randomised by block randomisation to receive either
docetaxel 75mgm
 2 on day 1 (D arm) or docetaxel 60mgm
 2 and
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sirinotecan 200mgm
 2 both on day 1 followed by lenogastrim
150mgm
 2day
 1 on days 2–12 (DI arm). Docetaxel (in 250ml
0.9% NaCl) was administered as a 1-h intravenous infusion in both
treatment arms. Irinotecan (3mgml
 1, diluted with 0.9% NaCl)
was administered after docetaxel as a 90-min infusion. Lenogas-
trim ampoules contained 263mg recombinant human granulocyte
colony-stimulating factor dissolved in 1ml solvent for subcuta-
neous injection. Treatment was repeated every 3 weeks for a
maximum of five cycles and halted in case of tumour progression,
intolerable toxicity or patient’s wish. To prevent hypersensitivity
reactions caused by docetaxel dexamethason 8mg was given twice
a day during 3 subsequent days starting the day before infusion.
Antiemetics consisted of ondansetron 8mg twice a day on days 1–
3. In case of diarrhoea, patients were treated with loperamide
(starting dose 4mg, followed by 2mg every 2h as long as diarrhoea
continued, maximum dose 16mg per day). When the diarrhoea
persisted for more than 48h or occurred in combination with
neutropenia, fever or dehydration, patients were hospitalised and
treated with antibiotics.
Dose adjustments
Drug administration was postponed (maximally 2 weeks) if there
was no haematologic recovery on day 22 (leukocytes
o3.0 10
9l
 1 and/or platelets o100 10
9l
 1). In case of nadir
values of neutrophils o0.5 10
9l
 1 or platelets o50 10
9l
 1
exceeding 7 days, febrile neutropenia, or thrombocytopenia
associated with bleeding, the dose of docetaxel for subsequent
cycles was reduced to 55mgm
 2 in the D arm and to 45mgm
 2 in
the DI arm. The dose of irinotecan was reduced to 150mgm
 2 in
these cases. In the event of grade 3–4 nonhaematologic toxicity
(except nausea and vomiting) or grade 2 neuropathy, the doses of
docetaxel and irinotecan were reduced with 25% for subsequent
cycles. Treatment was stopped if the same severity of toxicity
occurred at the reduced dose level treatment or in case of grade 3–
4 neuropathy. In case of grade 3–4 diarrhoea lasting more than 2
weeks despite appropriate therapy, no further irinotecan was
administered.
Treatment evaluation
Complete blood cell counts were performed weekly during
treatment. On day 1 of each cycle, patient evaluation also included
liver and renal functions, performance status, chest X-ray, and
toxicity scoring according to CTC. All patients were evaluable for
toxicity. Tumour response was evaluated according to World
Health Organisation criteria (1979).
After discontinuation of treatment, physical examination,
laboratory tests, chest X-ray, and additional imaging tests on
clinical indication to assess tumour progression were performed
every 6 weeks.
Statistical analysis
The ‘pick the winner’ format based on the randomised phase II
clinical trials approach as proposed by Simon et al (1985) was
used. In this approach, an accrual of 53 patients in each arm gives
a 90% chance of selecting the better treatment schedule if the
difference in response rate is at least 10% and the smaller response
rate is assumed to be approximately 15%. The arm with the highest
response rate is declared the ‘winner’ providing that the response
rate is at least 15%. A statistically significant difference in response
rate is not required in this trial design. This trial design is not
suitable to test hypotheses of equality of effects. Moreover, with
this approach, a treatment can still be selected even if the
difference in response rate is less than 10%, but then the
probability of correct selection will not be as great as 90%.
In order to terminate an ineffective schedule early in the study
a three-stage stopping rule was used, as proposed earlier by
Hoskins et al (1998). The conclusion from this study would be
based on the ranking of the response rate. No formal statistical
comparison between the two arms was planned for the primary
end point.
Patient characteristics, treatment parameters, and toxicity
in both arms were compared using Student’s t-test, Mann–
Whitney test, w
2 test, or Fisher’s exact test. The time from the
date of randomisation to the date of first documented progression
was defined as progression-free survival. Overall survival was
defined as the interval between the date of randomisation and the
date of death. Survival data were compared by Kaplan–Meier
curves using the log-rank test. A Po0.05 was considered
statistically significant.
RESULTS
Patient characteristics
Between October 2000 and January 2003, 108 patients from five
hospitals in the Netherlands were randomised to D (n¼56) or DI
(n¼52). Patient characteristics were not significantly different
between both treatment arms (Table 1).
Toxicity
Haematologic toxicity is shown in Table 2. In the D arm, grade 3 or
4 leukopenia and granulocytopenia occurred more frequently as
compared to the DI arm. However, in both arms, an equal number
of patients was hospitalised for febrile neutropenia. Significantly
more patients in the DI arm had thrombocytopenia. Anaemia
occurred in both arms at equal frequency. At the time of study,
erythropoietin was not routinely administered.
The worst nonhaematologic toxicity per patient is listed in
Table 3. Diarrhoea was more frequently observed in the DI arm
(Po0.01). In this arm, six patients were hospitalised for serious
diarrhoea compared to one patient in the D arm (P¼0.05). Nail
changes and arthralgia were only observed in the D arm, where the
higher docetaxel dose was administered. Additionally, significantly
more patients in the D arm had myalgia (Po0.05).
Treatment
A total of 206 and 162 cycles were administered in the D and DI
arm, respectively. The median (range) number of cycles per patient
was 4 (1–5) in the D arm, and 3 (1–5) in the DI arm. The
maximum of five cycles was completed in 25 (45%) patients in the
D arm and in 17 (33%) patients in the DI arm (P40.05). The
reasons for treatment discontinuation for both arms were not
different. Main reasons for treatment discontinuation were
progressive disease and toxicity. Seven patients died due to disease
progression while on protocol therapy. Three patients died due to
toxicity of treatment, due to paralytic ileus after one cycle (n¼1; D
arm), bowel perforation after two cycles (n¼1; DI arm), and
myocardial infarction after one cycle (n¼1; DI arm). Doses of
docetaxel (D arm), docetaxel (DI arm), and irinotecan had to be
reduced in 4, 2, and 7% of the cycles, respectively. In both arms,
drug administration was postponed up to 2 weeks in 2% of the
cycles.
Tumour response
At the end of the first stage, one response was observed in the D
arm vs two in the DI arm. A total of five responses was observed in
both arms at the end of the second stage. Subsequently, enrolment
Second-line docetaxel and irinotecan in NSCLC
FM Wachters et al
16
British Journal of Cancer (2005) 92(1), 15–20 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
scontinued to a total of 108 patients. Final analysis revealed an
overall response rate of 16% (95% CI, 6–26) for the D arm and
10% (95% CI, 2–18) for the DI arm (Table 4). According to
the statistical design of this trial, the D arm was declared the
‘winner’. Nine patients were not evaluable for tumour response
due to early death (n¼1; D arm, n¼2; DI arm), discontinuation of
treatment at patients request (n¼1; D arm), and discontinuation
for toxicity (n¼5; DI arm). These patients were considered
nonresponders.
Progression-free survival and overall survival
In August 2003, 22 patients were still alive. The median
progression-free survival was not significantly different between
both treatment arms; 18 (95% CI, 16–21) vs 15 (95% CI, 12–18)
weeks for the D and DI arm, respectively (P¼0.42) (Figure 1). The
median overall survival was 32 (95% CI, 25–40) weeks in the D
arm, vs 27 (95% CI, 8–46) weeks in the DI arm, which was not
different between both arms (P¼0.69). The 1-year survival rate
(7s.e.) was 26% (76%) vs 30% (77%) in the D and DI arm,
respectively (P¼0.49) (Figure 2).
DISCUSSION
According to the statistical design of this trial, the docetaxel arm,
with a response rate of 16%, ranked superior compared to the
docetaxel–irinotecan arm, with a response rate of 10%. Using this
design, smaller number of patients are required compared to the
usual randomised trial design in which sample size calculations are
based on statistical significance. The conclusion of this trial – that
addition of irinotecan to docetaxel as second-line chemotherapy in
NSCLC does not improve response rate – is solely based on the
ranking of response rate. Although our trial was not powered to
detect differences in survival, the efficacy of docetaxel as single
agent and docetaxel combined with irinotecan seemed not
different in terms of progression-free survival and overall survival.
Both arms showed a different toxicity profile. Leukopenia, nail
changes, myalgia, and arthralgia occurred more frequently in the D
arm, while thrombocytopenia and diarrhoea were more common
in the DI arm. Toxicities especially occurring in the D arm might
probably be related to the higher dose level of docetaxel used in
this arm. Nevertheless, toxicity in the docetaxel arm was
acceptable. As in other trials, diarrhoea frequently occurred after
treatment with docetaxel and irinotecan (Adjei et al, 2000; Masuda
et al, 2000; Satouchi et al, 2001). In the majority of patients, in this
trial, diarrhoea resolved after treatment with loperamide. An
option for prevention of delayed-type diarrhoea (occurring 424h
after irinotecan administration) is administration of the poorly
absorbed aminoglycoside antibiotic neomycin, which decreases the
intestinal SN-38 (active metabolite of irinotecan) concentration by
inhibition of b-glucuronidase activity from intestinal microflora
(Kehrer et al, 2001).
The response rate for docetaxel monotherapy found in this trial
is comparable to results of other phase II trials, which found a
response rate between 16–22% (Fossella et al, 1995; Gandara et al,
2000; Robinet et al, 2000). In two phase III trials a lower response
rate (7–11%) was reported (Fossella et al, 2000; Shepherd et al,
2000). Median survival for docetaxel monotherapy in our study
was 7.5 months. The two mentioned phase III trials reported a
Table 2 Worst haematologic CTC toxicity grade per patient for all
cycles
Docetaxel Docetaxel–Irinotecan
Toxicity No. % No. % P
Anaemia NS
13 9 7 0 2 8 5 4
21 1 2 0 1 4 3 0
3/4 0 0 5 10
Leukopenia o0.05
1 6 11 6 12
21 6 2 9 7 1 3
3/4 16 29 7 13
Granulocytopenia
a o0.05
11 4 2 7
27 2 5 1 4
3/4 12 43 6 22
Thrombocytopenia o0.05
15 9 1 3 2 5
21 2 2 4
3/4 0 0 2 4
Febrile neutropenia 3 5 3 6 NS
aNeutrophil granulocyte counts were only available in 55 patients. NS¼Not
significant.
Table 1 Patient characteristics
Docetaxel Docetaxel–Irinotecan
No. % No. % P
Patients entered 56 52 NS
Age (years) NS
Median 59 58
Range 36–78 42–76
Sex NS
Male 44 79 32 62
Female 12 21 20 38
Stage NS
IIIb 14 25 11 21
IV 42 75 41 79
Performance status NS
01 0 1 8 1 3 2 5
13 9 7 0 3 7 7 1
27 1 3 2 4
Histology NS
Squamous cell carinoma 17 30 10 19
Adenocarcinoma 25 45 22 42
Large cell carcinoma 11 20 19 37
Other 3 5 1 2
Previous radiotherapy
To primary tumour 16 29 14 27 NS
To metastases 10 18 4 8 NS
First-line chemotherapy NS
Platinum-based 40 71 39 75
Nonplatinum-based 16 29 13 25
RR to first-line chemotherapy NS
%5 4 4 8
95% CI 41–67 34–62
Treatment interval (weeks)
a NS
Median 35 29
Range 2–167 1–147
NS¼not significant, RR¼response rate, CI¼confidence interval.
aInterval between
completion of previous chemotherapy and the date of randomisation.
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smedian survival of 7.5 and 5.7 months, respectively (Fossella et al,
2000; Shepherd et al, 2000).
Two other single agents were recently investigated in a second-
line setting in NSCLC patients. Gefitinib, an orally active EGFR
tyrosine kinase inhibitor, was studied in a randomised phase II
trial (Fukuoka et al, 2003). Antitumour activity, with a response
rate between 18 and 19%, as well as symptom relief and
improvement in quality of life was reported. Median survival was
between 7.6 and 8.0 months. Pemetrexed, a novel multitargeted
antifolate, was compared to single-agent docetaxel in a recently
published phase III trial (Hanna et al, 2004). No significant
differences in response rate and survival were found between
Table 4 Tumour response after second-line chemotherapy in advanced
NSCLC
Docetaxel Docetaxel–Irinotecan
Response No. % No. %
Complete response 1 2 0 0
Partial response 8 14 5 10
Stable disease 25 45 22 42
Progressive disease 20 36 18 35
Not assessable 2 4 7 14
Overall response (95% CI) 16 (6–26) 10 (2–18)
Time (weeks)
120 100 80 60 40 20 0
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
0.0
0.2
0.4
0.6
0.8
1.0
Docetaxel (n = 56)
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Log-rank: P = 0.419
Figure 1 Progression-free survival after second-line chemotherapy in
advanced NSCLC.
Table 3 Worst nonhaematologic CTC toxicity grade per patient for all
cycles
Docetaxel Docetaxel–Irinotecan
Toxicity No. % No. % P
ASAT NS
16 1 1 4 8
21 2 0 0
30 0 1 2
ALAT NS
12 0 3 6 1 8 3 5
24 7 3 6
Creatinine NS
12 1 3 8 8 1 5
21 2 3 6
30 0 1 2
Mucositis NS
1 8 14 5 10
21 2 0 0
Nausea NS
11 5 2 7 1 4 2 7
25 9 1 2 2 3
Vomiting NS
11 1 2 0 9 1 7
24 7 4 8
Diarrhoea o0.01
11 1 2 0 2 1 4 0
24 7 1 1 2 1
31 2 7 1 4
Fever NS
15 9 2 4
22 4 0 0
Infections NS
13 5 2 4
20 0 2 4
31 2 0 0
Alopecia o0.05
11 5 2 7 6 1 2
21 6 2 9 2 5 4 8
Skin reactions NS
12 4 0 0
23 5 0 0
Sensory neuropathy NS
11 3 2 3 1 0 1 9
24 7 1 2
Motoric neuropathy NS
12 4 0 0
20 0 0 0
30 0 1 2
Anorexia NS
11 6 2 9 1 6 3 1
24 7 4 8
Fatigue NS
12 3 4 1 1 3 2 5
21 2 2 1 1 8 3 5
Nail changes 0.052
15 9 0 0
21 2 0 0
Table 3 (Continued)
Docetaxel Docetaxel–Irinotecan
Toxicity No. % No. % P
Myalgia o0.05
11 2 2 1 3 6
22 4 0 0
Arthralgia o0.05
15 9 0 0
NS¼Not significant.
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spatients in both arms. Response rate and survival were in
accordance with other data on single-agent docetaxel as second-
line treatment (Fossella et al, 2000; Shepherd et al, 2000). However,
in the pemetrexed arm less toxicity, especially febrile neutropenia,
was observed. Therefore, pemetrexed can probably be used as
alternative reference regimen in the second-line treatment of
advanced NSCLC.
Whether combinations are superior to single agents in second-
line setting is presently unclear. Although this trial demonstrated
no clear benefit using docetaxel with irinotecan, other regimens
using the combination of these drugs with filgrastrim support or
with celecoxib are currently under investigation (Argiris, 2003;
Frasci et al, 2004).
In conclusion, addition of irinotecan to docetaxel as second-line
chemotherapy does not improve response rate, and increases
gastrointestinal toxicity in patients with stage IIIb or IV NSCLC.
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